5-methyl-2-phenyl-1,3-dioxane | 27942-89-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二恶烷
• 英文名称: 5-methyl-2-phenyl-1,3-dioxane
• CAS: 27942-89-8
• 化学式: C₁₁H₁₄O₂
• 分子量: 178.231
• InChiKey: FSXSFJIPYVZFBE-UHFFFAOYSA-N

物化性质

• 沸点：
  266.1±25.0 °C(Predicted)
• 密度：
  1.031±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-methyl-2-phenyl-1,3-dioxane 在 二异丁基氢化铝 作用下， 以 正己烷 、 甲苯 为溶剂， 生成 (RS)-3-苄氧基-2-甲基丙醛
  参考文献：
  名称：

  Chemoenzymatic Approach toward the Pure Enantiomers of 2-Methyl-1,3-propanediol Mono(p-Methoxybenzyl Ether)

  摘要：

  In a route towards the enantiomerically pure 2-methylpropane-1,3-diol mono(p-methoxybenzyl ether), which is an important starting material for natural product synthesis, a kinetic resolution approach by means of lipase-catalyzed hydrolysis as well as acylation has been elaborated. Candida antarctica lipase-catalyzed hydrolysis of the corresponding racemic acetate proceeded with high enantioselectivity (E 35). During the studies, a curious phenomenon was observed, namely, that the enantioselectivity gradually declined accompanying the progress of the hydrolysis. This was due to inhibition of the enzyme-catalyzed reaction caused by the accumulation of the resultant alcohol. The rate of reaction of the more reactive enantiomer became lower. This situation prompted a new process, which would minimize the contamination or the undesired enantiomer, prior to the enzyme-catalyzed hydrolysis. This was successfully achieved with the aid of another Pseudomonas cepacia lipase-catalyzed desymmetrization, taking advantage of the prochiral nature of the starting material, 2-methyl-1,3-propanediol, and the subsequent p-methoxybenzylation under mild conditions.

  DOI：

  10.1002/1615-4169(200108)343:6/7<624::aid-adsc624>3.3.co;2-h
• 作为产物：
  描述：

  2-甲基-1,3-丙二醇 、 苯甲醛 在 对甲苯磺酸 作用下， 以 苯 为溶剂， 以98%的产率得到5-methyl-2-phenyl-1,3-dioxane
  参考文献：
  名称：

  （+）-（R）-甲基对甲苯基亚砜与腈反应的手性β-酮亚砜的新型合成

  摘要：

  通过与由（+）-（R）-甲基对甲苯基亚砜形成的阴离子反应和在水溶液中进行酸性后处理，腈官能团可有效地转化为β-酮亚砜部分。

  DOI：

  10.1016/s0040-4039(99)01951-6

文献信息

• A new and general synthesis of chiral β-ketosulfoxides by reaction of (+)-(R)-methyl p-tolyl sulfoxide with nitriles
  作者：Robert Vleggaar、Jacob G. Zeevaart

  DOI：10.1016/s0040-4039(99)01951-6

  日期：1999.12

  The nitrile functional group is efficiently transformed into the β-ketosulfoxide moiety by reaction with the anion formed from (+)-(R)-methyl p-tolyl sulfoxide and aqueous acidic work-up of the reaction.

  通过与由（+）-（R）-甲基对甲苯基亚砜形成的阴离子反应和在水溶液中进行酸性后处理，腈官能团可有效地转化为β-酮亚砜部分。
• [EN] NR2B-SELECTIVE NMDA-RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS NMDA SÉLECTIFS DU SITE NR2B
  申请人：UNIV MUENSTER WILHELMS

  公开号：WO2010122134A1

  公开（公告）日：2010-10-28

  The present invention relates to compounds according to general formula (I) and pharmaceutical compositions comprising compounds according to general formula (I).

  本发明涉及符合一般式（I）的化合物以及包含符合一般式（I）的化合物的药物组合物。
• Graphene-catalyzed transacetalization under acid-free conditions
  作者：Medy C. Nongbe、Nicolas Oger、Tchirioua Ekou、Lynda Ekou、Benjamin K. Yao、Erwan Le Grognec、François-Xavier Felpin

  DOI：10.1016/j.tetlet.2016.09.022

  日期：2016.10

  1,2- and 1,3-Diols are readily protected as cyclic acetals and ketals through a graphene-catalyzed transacetalization process. The methodology features an atom economic procedure since quasi-stoichiometric conditions have been developed. Unlike prior systems, the graphene-catalyzed transacetalization is performed under Brønsted and Lewis acid-free conditions and without solvent. Our method has been

  1,2-和1,3-二元醇通过石墨烯催化的反缩醛化过程很容易被保护为环状缩醛和缩酮。由于已经开发了准化学计量条件，因此该方法具有原子经济程序的特点。与现有系统不同，石墨烯催化的缩醛化反应是在无布朗斯台德和路易斯酸的条件下且没有溶剂的情况下进行的。我们的方法已应用于不适合复杂后处理和大量纯化步骤的几种挥发性化合物。石墨烯对缩醛化反应的非常不同寻常的催化性能归因于石墨烯与底物之间的分子电荷转移。
• NR2B-selective NMDA-receptor antagonists
  申请人：Westfälische Wilhelms-Universität Münster

  公开号：EP2246331A1

  公开（公告）日：2010-11-03

  The present invention relates to NMDA antagonists that target the NR2B subunit according to general formula (I) and pharmaceutical compositions comprising compounds according to general formula (I).

  本发明涉及根据通式（I）靶向 NR2B 亚基的 NMDA 拮抗剂和包含根据通式（I）化合物的药物组合物。
• MEDICINAL ARYLETHANOLAMINE COMPOUNDS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1554264B1

  公开（公告）日：2007-08-08